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The Course of Response to Focal/ Grid Photocoagulation for
Diabetic Macular Edema
The Diabetic Retinopathy Clinical Research Network
Abstract
Purpose—To determine whether eyes with center involved diabetic macular edema (DME), treated
with focal/grid photocoagulation, in which there is a reduction in central subfield thickness (CST)
measured with optical coherence tomography (OCT) after 16 weeks, will continue to improve if
retreatment is deferred.
Methods—Prospective, multi-center, observational, single group focal/grid photocoagulation study
of 122 eyes with center involved DME (OCT CST ≥250μ). At the 16-week visit and continuing every
8 weeks, eyes were assessed for retreatment and additional laser was deferred if the visual acuity
letter score improved ≥5 letters or OCT CST decreased ≥10% compared with the visit 16 weeks
prior.
Results—Of the 115 eyes that completed the 16-week visit, 54 (47%) had a decrease in CST by
≥10% compared with baseline. Of these, 26 (48%) had a CST ≥250μ at 16 weeks and were evaluable
at 32 weeks. Eleven (42%, 95% confidence interval 23% to 63%) of the 26 eyes had a further decrease
in CST ≥10% from 16 to 32 weeks without further treatment.
Conclusion—Sixteen weeks following focal/grid laser for DME, in eyes with a definite reduction,
but not resolution, of central edema, 23% to 63% will continue to improve without additional
treatment.
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Introduction
Focal/grid photocoagulation (focal/grid) is the standard treatment for diabetic macular edema
(DME).1 Repetitive photocoagulation was the norm in the Early Treatment Diabetic
Retinopathy Study (ETDRS) with a median of 3.8 treatments applied over three years of follow-
up (Ferris FL, unpublished data). Retreatment was applied at 4 month intervals if clinically
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Summary Statement:
Some eyes with diabetic macular edema that improve in retinal thickness but have persistent edema 16 weeks following focal/grid
photocoagulation will continue to improve without additional treatment.
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significant macular edema persisted, one or more treatable lesions were identified, and the
investigator believed these lesions were responsible for the edema.1
Studies have shown that photocoagulation can result in retinal pigment epithelial atrophy 200–
300% larger than the original laser spot size and can cause secondary choroidal neovascular
membranes.2–4 These complications can lead to loss of central vision, paracentral scotomata,
and decreased color vision. Consequently, many retinal specialists today tend to treat with
lighter, less intense laser burns than originally specified in the ETDRS,5 although no clinical
trials have been done to show improved outcomes with this approach. Other modifications in
the treatment procedures originally specified in the ETDRS protocol have been made without
clinical trial evidence of their superiority. These include specification that maximal spot size
be 50 microns, allowing the use of yellow wavelength as well as green, not requiring blanching
of large microaneurysms as long as the subjacent retinal pigment epithelium is lightly blanched,
and removing the requirement for fluorescein angiography to guide treatment.6, 7 A modified
ETDRS focal/ grid photocoagulation protocol including all these changes has been adopted as
the standard laser technique for DME used in Diabetic Retinopathy Clinical Research Network
(DRCR.net) studies. (www.drcr.net)
An important aspect of focal/grid photocoagulation concerns re-treatment guidelines. In the
present work, we investigate this topic. There are limited data on the course of visual acuity
and central retinal thickness after a single photocoagulation session for DME. In a DRCR.net
clinical trial comparing serial injections of intravitreal triamcinolone with serial focal/ grid
photocoagulation treatments, eyes with persistent center involved edema were to receive a
second photocoagulation session at 3.5– 4 months unless there was substantial improvement
defined as at least a 50% decrease in retinal thickening of the central subfield measurement on
Optical Coherence Tomography (OCT).(8, 9) In a DRCR.net study currently comparing various
combination therapies to focal/ grid laser alone, eyes are to receive a second photocoagulation
session at 4 months whenever a central subfield thickness (CST) ≥ 250 microns and treatable
lesions or thickened macular regions without previous grid treatment are present (protocol
available at www.drcr.net date accessed, March 2, 2009). As a result, it is unknown what
proportion of eyes with lesser degrees of reduction in retinal thickness would have continued
to improve and what the time course for further improvement following the initial
photocoagulation session might be. Information derived from four DRCR.net studies (N = 478)
indicated that 221 eyes (46%) receiving focal/ grid photocoagulation showed at least 10%
improvement in central retinal thickness after 3–4 months (DRCR.net, unpublished data). Of
these 221 eyes, 154 (70%) still remained ≥ 250 microns in the central subfield despite the 10%
improvement in thickness. It is for these eyes that further knowledge of the course of retinal
thickening and visual acuity without additional interventions is needed to assess how often
continued improvement might occur in the absence of additional treatment.
We performed a study designed to determine the effect of deferral of retreatment in eyes that
were improving after initial focal/ grid laser treatment, but still had residual macular edema 16
weeks later. This information might help guide focal/ grid laser re-treatment protocols, and
help investigators decide if a randomized clinical trial is justified comparing the current
DRCR.net re-treatment regimen versus a regimen of more prolonged observation before
retreatment when improvement occurs.
Methods
This prospective, multi-center, single-group intervention study of subjects with center involved
DME (OCT mean CST ≥250 microns) was conducted by the DRCR.net at 26 clinical sites
throughout the United States. The protocol and HIPAA-compliant informed consent forms
were approved by multiple institutional review boards. Each subject gave written informed
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consent to participate in the study. The study is listed on www.clinicaltrials.gov, under
identifier NCT00442156 and the protocol is available on the DRCR.net website
(www.drcr.net) and summarized below.
Study Population
Eligible subjects had to be at least 18 years old with type 1 or type 2 diabetes. Subjects were
excluded if they had a history of chronic renal failure requiring dialysis, poor glycemic control
in which intensive insulin treatment had been given in the previous 4 months, blood pressure
systolic above 180 or diastolic above 110. Study eyes were to have the following: (1) best
corrected electronic-ETDRS (E-ETDRS) visual acuity letter score ≥ 24 (Snellen equivalent of
20/320 or better), (2) retinal thickening due to DME involving the center of the macula on
clinical exam, (3) retinal thickness in the central subfield measured on a Stratus (Carl Zeiss
Meditec, Dublin, CA) OCT ≥ 250 microns, and (4) focal/grid photocoagulation planned as
treatment for DME. A study eye was not eligible if (1) it had received treatment for DME in
the past 4 months, had received panretinal (scatter) photocoagulation in the prior 4 months or
for which treatment was planned in the next 6 months; (2) had a history of major ocular surgery
(including cataract extraction, vitrectomy, scleral buckle, any intraocular surgery) within the
prior 4 months or anticipated within the subsequent 6 months, or (3) had a history of YAG
capsulotomy performed within the previous 2 months. A subject could have only one study
eye.
Synopsis of Study Design
Study eyes received focal/grid photocoagulation and were evaluated for change in visual acuity
letter score and OCT CST. Follow-up visits with these measurements were performed at 8-
week intervals until exiting the study or out to 48 weeks within pre-specified time windows.
At the 8-week visit no treatment decisions were made. At week 16, eyes were classified as
improved and further laser was deferred if the VA letter score improved by ≥5 letters or OCT
CST decreased by ≥10% compared with baseline. For visual acuity a 5 letter score or greater
improvement was considered a real change based on the 95% confidence interval for change
determined in a study that evaluated the validity and reliability of the E-ETDRS visual acuity
testing procedure that is used in DRCR.net protocols.10 The 10% CST threshold is based on
the DRCR.net OCT reproducibility study which found that a 10% or greater change in CST
was likely to be real.11 Eyes that improved at week 16 were evaluated every 8 weeks and
considered for further treatment deferral if the visual acuity letter score or OCT CST improved
compared to the visit 16 weeks earlier. If eyes did not improve as described above according
to the visual acuity letter score or OCT at any visit starting with week 16 and additional laser
was given, the subject exited the study. Eyes that did not improve, but for whom laser was
deferred (at the investigator’s discretion) also were evaluated every 8 weeks until laser was
given or through 48 weeks.
Examination Procedures
At baseline, best-corrected visual acuity was measured at 3 meters. A certified visual acuity
examiner completed a refraction following DRCR.net specific protocol and visual acuity
testing using the ETDRS electronic method .10 Optical coherence tomography images were
obtained through a dilated pupil by a certified operator using the Zeiss Stratus OCT machine
(Carl Zeiss Meditec, Dublin, CA) Scans were 6 mm in length and included the 6 radial line
fast macular scan pattern for quantitative measures and the cross-hair pattern (6 to 12 o’clock
and 9 to 3 o’clock for qualitative assessment of retinal morphologic features). Images with a
center point standard deviation ≥10% of the center point mean were sent to the DRCR.net
Reading Center at the University of Wisconsin-Madison for grading.
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If the automated thickness measurements were judged by the Reading Center to be inaccurate,
center point thickness was measured manually, and this value was used to impute a value for
the central subfield (based on a correlation of the 2 measures of 0.98 as published previously
imputation was used for 9% of scans). 12
Treatment Protocol
The focal/grid photocoagulation technique was modified from the original ETDRS protocol
as described previously and used in prior DRCR.net protocols.7 Laser photocoagulation burns
were less intense (light gray) and were limited to a smaller spot size (50 μ instead of 50 to 200
μ) than in the original ETDRS protocol.13 Any laser wavelength between green and yellow
was allowed. Blanching of microaneurysms was not required as long as a light gray color
change was produced in the subjacent retinal pigment epithelium. In general laser
photocoagulation was completed in one sitting and involved focal treatment to all leaking
microaneurysms and grid treatment to areas of retinal thickening. The use of a fluorescein
angiogram to direct treatment was at investigator discretion.
Statistical Methods
A convenience sample size of approximately 110 eyes was selected for this study. A total of
128 subjects were enrolled, of which 6 subjects were excluded from analysis due to an ineligible
baseline OCT (CST <250 microns); 2 of these were due to site errors and 4 were a result of
manual grading through Reading Center assessment.
The main outcome measure was the proportion of subjects with improvement in OCT-
measured CST by 10% or more at the 32-week follow-up visit compared with the value at the
16- week visit. Per protocol, subjects treated at the 24-week visit were discontinued from the
study. These subjects were considered failures for the primary outcome of change from 16 to
32 weeks. Changes in visual acuity letter score for subjects meeting the primary outcome are
described.
Distributions of improvement were tabulated and 95% confidence intervals were calculated.
Subjects who missed the 16, 32, or 48 week visits were excluded from the analysis at that time
point. SAS software version 9.1 (SAS, Cary, NC) was used for all analyses.
Results
Between January and June 2007, 26 sites enrolled 122 eligible study eyes with center involved
DME. The baseline characteristics are reported in Table 1.
Macular Thickness Outcomes
Of the 122 eligible study eyes, 115 (94%) completed the 16-week visit. Of these, 54 (47%)
had a reduction in CST on OCT by at least 10% compared with baseline with 26 having CST
< 250 microns at 16 weeks. Since eyes with CST < 250 microns at 16 weeks were unlikely to
improve further by a substantial amount, these 26 eyes were not evaluated for further
improvement at subsequent visits in this analysis.
Among the remaining 28 eyes (23%) with persistent edema that improved from baseline to 16
weeks, a further reduction in CST by 10% or more was evaluated by comparing the OCT CST
at the 32 week visit with the CST at the 16 week visit. Twenty-six of the 28 eyes were evaluable
at 32 weeks; 4 of the 26 evaluable eyes were treated at the 24-week visit. These 4 eyes were
assumed to be failures. Of the 26 eyes, 11 (42% [95% CI 23–63%]) eyes showed reduction of
CST by at least 10% from 16 to 32 weeks (Table 2). Thus, continuing improvement from 16
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to 32 weeks was seen in 11 of 115 (10%) eyes overall in this study. Seven (58%) of the 12 eyes
evaluated at 32 weeks with baseline OCT CST ≥ 400 microns showed an OCT CST reduction
from 16 weeks to 32 weeks, compared with 4 (29%) of 14 eyes with baseline OCT CST < 400
microns. The OCT CST at the 48-week visit was also compared with the thickness at the 32-
week visit in the same 11 eyes. One subject missed the 48-week visit and was excluded,
resulting in 10 evaluable eyes. In 8 of these 10 eyes CST at 32 weeks was < 250 microns and
in the remaining 2 eyes retreatment was carried out in conjunction with the 40 week visit.
Table 3 summarizes the macular thickness and re-treatment course followed after the 16-week
visit by the 54 eyes that met the OCT CST improvement criterion and the 16 eyes that met
only the visual acuity improvement criterion. The 54 eyes meeting the OCT criterion were
classified by whether CST was ≥ or < 250 μ at the 16 week visit. In the group with CST < 250
μ, at the last visit CST was < 250 μ in 19 eyes, ≥ 250 μ in 3 eyes, and 3 eyes had been re-treated
with focal/ grid photocoagulation prior to the last visit. In the group with CST ≥ 250 μ at 16
weeks, at the last visit CST was < 250 μ in 12 eyes, ≥ 250 μ in 5 eyes, and 10 eyes had been
re214 treated with focal/ grid photocoagulation prior to the last visit. Meeting the visual acuity
deferral criterion alone at week 16 did not predict the possibility of deferral of re-treatment
through 48 weeks of follow-up. Of 14 such eyes with follow-up, 11 were re-treated prior to
the last visit and 2 had CST ≥ 250 μ at the last visit.
Visual Acuity Outcomes
Of the 26 evaluable eyes that improved on OCT from baseline but had persistent edema at 16
weeks, 7(27%) also improved by 5 or more letters (1 line) in E-ETDRS visual acuity at 16
weeks. Of the 11 eyes that further improved in OCT CST from 16 weeks to 32 weeks, 4(36%)
improved in visual acuity letter score by at least 5 letters, 6 (55%) remained the same (changed
by less than 5 letters), and 1 (9%) worsened by at least 5 letters.
At the 16-week visit, 16 eyes improved in visual acuity but did not improve in OCT CST
compared with baseline. At the 32-week visit 1 of the 16 eyes had improved in OCT CST from
the 16-week visit and from baseline and 10 of the 16 eyes were treated at 24 or 32 weeks. Of
the 54 eyes with ≥ 10% reduction in macular thickening at 16 weeks, 10 (19%) showed ≥ 5
letter loss, whereas 19 (35%) improved by ≥ 5 letters.
Discussion
Focal/ grid photocoagulation has been shown to improve visual acuity outcomes in DME
compared with no treatment, and to result in superior 2 year visual and macular thickness
outcomes compared with serial injections of intravitreal triamcinolone.9, 13 It is possible that
similar or better outcomes might be achieved with fewer focal/grid treatments if current
guidelines for laser re-treatment were revised to observe and defer additional treatment in
improving eyes if incomplete resolution of macular edema is observed after initial
photocoagulation, a situation applicable to 32% of eyes based on DRCR.net studies. Focal/
grid photocoagulation has potential side effects, including laser scar expansion, paracentral
scotomata, elevation of central visual field thresholds, and secondary choroidal
neovascularization and subretinal fibrosis.2–4, 14 Modifications to focal/grid photocoagulation
technique have been made already in response to these potential side effects. Although clinical
trials have not been performed to determine whether outcomes are equivalent with these
modifications, comparison across studies suggests that outcomes with current techniques may
be similar to those obtained with the original ETDRS technique. Re-treatment guidelines are
worthy of attention, because costs of time and money might be lessened if the benefits of focal/
grid photocoagulation in DME could be obtained with fewer treatment sessions.
Page 5
Retina. Author manuscript; available in PMC 2010 November 1.
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
N
IH
-PA Author M
anuscript
The results of this prospective, multicenter study suggest that using current treatment protocols,
23% of eyes may show improvement in macular thickness over 16 weeks without fully
resolving. In this subset of eyes, continued OCT improvement over the ensuing 16 weeks (from
16 to 32 weeks) occurs in 42% [95% CI 23–63%]. Thus, continuing improvement past 16
weeks is seen in 10% of eyes overall based on this study. Eyes with greater macular thickening
had a higher frequency of continued improvement after 16 weeks. We also found that the
criterion for re-treatment deferral based on visual acuity improvement alone proved to be
poorly predictive for subsequent deferral of re-treatment through 48 weeks of follow-up.
Eleven of 16 such eyes (69%) required re-treatment after the 16 week visit.
The precision of our results is limited by the small number of eyes studied, and the results do
not imply that visual acuity outcomes will be better if re-treatment is deferred at 16 weeks in
such eyes. It is possible that additional improvement might have occurred if treatment had not
been withheld at 16 weeks. A randomized clinical trial would be needed to assess whether
deferring additional treatment for improving eyes with persistent DME is of greater benefit
compared with retreating all eyes with center involved edema.
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Table 1
Baseline Characteristics
Total
N=122
Gender: Women – n (%) 60 (49%)
Age (yrs) - Median (25th, 75th percentile) 65 (57, 72)
Race- n(%)
    White 86 (70%)
    African-American 18 (15%)
    Hispanic or Latino 12 (10%)
    Asian 2 (2%)
    Other* 4 (3%)
Diabetes Type - n(%)
    Type 1 7 (6%)
    Type 2 115 (94%)
Duration of Diabetes (years) - Median (25th, 75th percentile) 19 (12, 24)
HbA1c (%) - Median (25th, 75th percentile) † 7.4 (6.6, 8.5)
Prior treatment for DME in study eye – n (%)
May have had more than one type of treatment
58 (48%)
    Focal/grid laser photocoagulation- n (%) 55 (45%)
    Intravitreal Corticosteroids- n (%) 18 (15%)
    Peribulbar Corticosteroids - n (%) 2 (2%)
    Anti-VEGF- n (%) 3 (2%)
Prior Panretinal Photocoagulation in study eye – n (%) 24 (20%)
E-ETDRS Visual Acuity (letter score)- Median (25th, 75th percentile) 72 (62, 79)‡
Central Subfield Thickness (microns)- Median (25th, 75th percentile) 330 (279, 402)
Retinal Volume (mm3)-Median (25th, 75th percentile)§ 7.9 (7.4, 8.8)
*
Other race category includes: American Indian/Alaskan Native, more than one race, and unknown.
†
3 subjects missing baseline HbA1c
‡
Snellen equivalent=20/40 (20/63,20/25)
§
4 subjects missing baseline retinal volume
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Table 2
Evaluation of OCT Improvement
N
Total # Enrolled N=128
 # ineligible 6
 # treated prior to 16 week visit 1
 # dropped/missed prior to 16 week visit 6
 # eligible completing 16 week visit 115
At 16-week visit N=115
 OCT CSF improved from baseline by ≥10%- N(%) 54(47%)
  OCT CSF < 250 μ- N (exited subsequent analyses) 26
  OCT CSF ≥ 250 μ -N 28
Improved from baseline and OCT CSF ≥ 250 μ at 16 weeks N=28
 # Treated prior to 32 week visit 4
 # Dropped/Missed prior to 32 week visit 2
 # Completed 32-week Visit 22
At 32-week visit (includes treated at 24 weeks) N=26
  OCT CSF improved from 16-week visit by >10% - N(%) 11(42%)
    OCT CSF < 250 μ -N 8
    OCT CSF ≥ 250 μ -N 3*
*
2 subjects were treated at 40 week visit, 1 subject missed 48 week visit
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Table 3
Course Followed Subsequent to Week 16 Visit
Status at week 16 No. OCT CSF
<250 microns
at all
subsequent
visits
OCT CSF
≥250 microns
at some visits
after 16 weeks
and not treated
(# < 250 at last
visit)
Treated No
visits
after
16
weeks
OCT CSF
decreased by
≥10%
N= 54
and <250
microns 26 18 4(1) 3 1
and ≥250
microns 28 4 13(8) 10 1
VA improved by ≥5 letters
and OCT CSF not
decreased by ≥10%
16 0 3(1) 11 2
Retina. Author manuscript; available in PMC 2010 November 1.
